SynthesisExploration of targeted anti-tumor therapy2026
Impact of smoking on subtypes and molecular profile of breast cancer: a systematic review.
Synthesis in Exploration of targeted anti-tumor therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Breast cancer encompasses heterogeneous pathological and molecular subtypes with distinct aetiologies and clinical outcomes. Although cigarette smoking is an established carcinogenic exposure, its subtype-specific associations and molecular effects in breast cancer remain insufficiently clarified. This systematic review synthesizes epidemiological, molecular, and prognostic evidence on how active cigarette smoking influences the risk of specific breast cancer subtypes. Methods: We conducted a systematic review, including observational and translational human studies that assessed active cigarette smoking in relation to breast cancer subtypes defined by estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) status, or by intrinsic molecular classifications. We also included studies evaluating smoking-associated molecular alterations within breast tumors. Results: Nineteen studies met the eligibility criteria. Epidemiological evidence suggested a possible modest increase in the risk of luminal/ER-positive breast cancer, particularly among women with longer smoking duration, heavier cumulative exposure, or smoking initiation before first full-term pregnancy; however, the pooled meta-analysis for current vs. never smoking was not statistically significant. No meaningful association was identified for triple-negative breast cancer (TNBC), and findings for HER2-positive breast cancer were heterogeneous. Molecular studies were associated with smoking-related changes in promoter DNA methylation, higher overall mutational burden, increased genomic instability, altered immune-cell infiltration within the tumor microenvironment, and conversion of receptor phenotype-especially toward HER2 positivity-suggesting a potential association with more aggressive tumor characteristics. Prognostic studies generally showed poorer overall survival and a higher risk of disease recurrence among smokers. Discussion: Active cigarette smoking may be associated with a possible modest increase in the risk of luminal/ER-positive breast cancer, while being associated with molecular alterations linked to more aggressive tumor phenotypes and poorer clinical outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.